Reportsnreports.com: Case Study: Sepsis - Xigris’ Disappointing Performance Creates a Market Opportunity for Improved Sepsis Therapies
Sepsis has high mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign (SSC) has helped to increase global awareness, standardize patient care, and reduce levels of mortality for sepsis. Negative clinical trial data have dented the commercial performance of Eli Lilly’s Xigris, creating an opportunity for improved sepsis therapeutics.
View full press release